Preview

Пульмонология

Расширенный поиск

Терапевтические возможности холинолитиков у больных хронической обструктивной болезнью легких

Полный текст:

Об авторе

А. В. Емельянов
Санкт-Петербургский государственный медицинский университет им. академика И. П. Павлова
Россия


Список литературы

1. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. N H L B I/ W H O workshop report.— National Heart, Lung, and Blood Institute. Publication 2701,2001.

2. Vereire P. The burden of chronic respiratory pulmonary disease. Respir. Med. 2002; 96 (suppl.C): S3-S10.

3. Barnes P. The pharmacological properties of thiotropium. Chest 2000; 117 (2, suppl.): 63S-66S.

4. Barnes P. Theoretical aspects of anticholinergic treatment. In: Gross N., ed. Anticholinergic therapy in obstructive airways dis ease. London: Franklin Scientific Publications; 1993. 88-104.

5. Barnes P., Belvesi M.G. et al. Tiotropium bromide (Ba 679 Br), a novel long-acting muscarinic antagonist the treatment of obstructive airways disease. Life Sci. 1995; 56 (11-12): 853-859.

6. Donahue J.F., van Noord J.A., Bateman E.D. et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122 (1): 47-55.

7. Martin R.J., Barielseon B.L., Smith P. et al. Effect of ipratropium bromide treatment on oxygen saturation and sleep quality in COPD. Chest 1999; 115 (5): 1338-1345.

8. Leisker J.J., Van De Velde V et al. Effect of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir. Med. 2002; 96 (8): 559-566.

9. Levin D.C., Little K.S., Laughlin K.R. et al. Addiction of anticholinergic solution prolongs bronchodilating effect of (32-agonists in patients with chronic obstructive pulmonary disease. Am. J. Med. 1996; 100 (1A): 40S-48S.

10. Taylor ]., Kotch A., Rice K. et al. Ipratropium bromide hydrofluoroalkane inhalation aerosol is safe and effective in patients with COPD. Chest 2001; 120 (4): 1253-1261.

11. Leisker J.J., Wijkstra P.J., Hacken T. et al. A systematic review of the effect of bronchodilators on exercise capacity in patients with COPD. Chest 2002; 121 (2): 597-608.

12. Matera M.G., Cazzola M., Vinciquerra A. et al. A comparison of the bronchodilating effects of salmeterol, saibutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm. Pharmacol. 1995; 8 (6): 267-271.

13. Chrischilles E., Gilden D., Kubisiak J. et al. Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease:effectiveness of two-in-one inhaler versus separate inhalers. Am. J. Manag. Care 2002; 8 (10): 902-911.

14. Friedman M., Serby C.VZ., Menjoge S. et al. Pharmacoecono mic evaluation of a combination of ipratropium plus albuterol compared with iptaropium and albuterol alone in COPD. Chest 1999; 115 (3): 635-641.

15. Chapman K.R., Arvidsson P., Chuchalin A.G. et al. The additional of salmeterol 50 meg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease. Can. Respir. J. 2002; 9(3) : 178-185.

16. Dlsse B., Speck G.A., Rominger K.L. et at. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci. 1999; 64 (6-7): 457-464.

17. Gupta R.K. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease. Indian J. Chest Dis Allied Sci. 2002; 44 (3): 165-172.

18. Jarvis B., Markham A. Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease. Drug Aging 2001 * 18 (6): 441-472.

19. Sichletldis L., Kottakis J., Marcou S. et al. Bronchodilatory response to formoterol, ipratropium, and their combination in patients with stable COPD. Int. J. Clin. Pract. 1999; 53 (3): 185-189.

20. Adkison J.D., Konzem S.L. Management of acute exacerbations of chronic obstructive pulmonary disease. Pharmacotherapy 2001; 21 (8): 929-939.

21. Hunter M.H., King D.E. COPD: management of acute exacerbations and chronic stable disease. Am. Fam. Physician. 2001; 64(4) : 603-612.

22. McCrory D., Brown C., Gelfand S.E., Baqch P.B. Management of acute exacerbations of COPD. A summary and appraisal of published evidence. Chest 2001; 119 (4): 1190-1200.

23. McCrory D., Brown C D. Inhaled short-acting P2_a&on*sts versus ipratropium for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2001; 2- CD 002984.

24. McCrory D., Brown C D. Anti-cholinergic bronchodilators versus P2-sympatomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst. Rev 2002. 4: CD 003900.

25. Snow V., Lascher S., Mottur-Pilson C. et al. The evidence base for management of acute exacerbations of COPD. Clinical practice guideline. Chest 2001; 119 (4): 1185-1189.

26. Casaburi R., Mahler D.A., Johnes P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19 (2): 217-224.

27. van Noord J.A., Bantie Th. A, Eland M.E. et al. A randomized controlled comparison of titropium and ipratropium in the treatment of COPD. Thorax 2000; 55 (4): 289-294.

28. Vincken W., van Noord A.P.M., Greefrost Th. A. et al. Improvement health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19 (2): 209-216.

29. D'Urzo A.D., De Salvo M.C., Ramirea-Rivera A. et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3 week, randomized, double blind, within- patient, multicenter study. Chest 2001; 119 (5): 1347-1356.

30. van Noord J.A., Smeets J.J., Custers F.L.J. et al. Pharmacodynamic steady state of tiotropium in patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19 (4): 639-644.

31. O'Donnel D.E., Lam M., Webb K.A. Spirometric correlated of improvement in exercise performance after cholinergic therapy in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: 542-549.

32. Sin D.D., Tu J.V. Lack of association between ipratropium bromide and mortality in elderly patients with chronic obstructive airway disease. Thorax 2000; 55 (3): 194-197.

33. Ayers M.L., Mejia R., Ward J. et al. Effectiveness of salmeterol versus ipratropium bromide on exertional dyspnoea in COPD. Eur. Respir. J. 2001; 17 (6): 1132-1137.


Для цитирования:


Емельянов А.В. Терапевтические возможности холинолитиков у больных хронической обструктивной болезнью легких. Пульмонология. 2004;(1):112-115.

For citation:


Emelianov A.V. Therapeutic abilities of cholinolytic drugs in patients with chronic obstructive pulmonary diseases. PULMONOLOGIYA. 2004;(1):112-115. (In Russ.)

Просмотров: 6


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)